Matches in SemOpenAlex for { <https://semopenalex.org/work/W1972185183> ?p ?o ?g. }
- W1972185183 endingPage "1220" @default.
- W1972185183 startingPage "1214" @default.
- W1972185183 abstract "Objectives. This study sought to examine plasma levels of soluble Fas/APO-1 receptor (sFas), an inhibitor of apoptosis, and soluble Fas ligand (sFas-L), an inducer of apoptosis, and their relation to each other and to other clinical variables, such as New York Heart Association functional class, tumor necrosis factor (TNF) and interleukin-6 (IL-6) in congestive heart failure (CHF). Background. It has been recently reported that apoptotic cell death occurs in myocytes of dogs with CHF. Hypoxia is frequently seen in advanced CHF and can stimulate Fas/APO-1 receptors (Fas) to induce apoptosis in cultured myocytes. Fas and Fas ligand (Fas-L) are cell-surface proteins and representative apoptosis-signaling molecules. Fas on the cell membrane induces apoptosis when it binds Fas-L or sFas-L. However, plasma sFas, a molecule lacking the transmembrane domain of Fas, blocks apoptosis by inhibiting binding between Fas and Fas-L or sFas-L on the cell membrane. At present, it is unknown whether plasma sFas-L and plasma sFas increase in the presence of cardiac disease. Methods. The study included 70 patients (mean [±SEM] age 65 ± 2 years, range 21 to 93) with chronic CHF (coronary artery disease in 28, dilated cardiomyopathy in 27, valvular heart disease in 15) and 62 age- and gender-matched normal control subjects. Plasma levels of sFas, sFas-L, TNF-alpha and IL-6 were measured by enzyme-linked immunosorbent assays using monoclonal anti-human antibodies. Results. There was no significant difference in sFas-L levels between normal subjects and patients in functional classes I to IV; however, sFas increased with severity of functional classification, independent of the underlying disease. sFas levels were significantly higher even in patients in functional class II than in normal subjects and those in functional class I, and were highest in patients in functional class IV (normal subjects: 2.2 ± 0.1 ng/ml; functional class I: 2.2 ± 0.2 ng/ml; functional class II: 3.1 ± 0.2 ng/ml; functional class III: 3.9 ± 0.3 ng/ml; functional class IV: 5.1 ± 0.6 ng/ml). Plasma sFas levels were significantly higher in patients with elevated pulmonary artery wedge pressure and a decreased cardiac index than in those with values in the normal range. In patients in functional class IV, there was no significant difference in plasma sFas levels between the survivors and nonsurvivors during 6-month follow-up. However, plasma levels of sFas tended to decrease in nine patients with clinical improvement (baseline sFas: 5.2 ± 0.8 ng/ml; 6-month sFas: 4.3 ± 0.5 ng/ml, p = 0.07) but were similar in patients with no change in functional class. TNF-alpha and IL-6 were increased significantly only in patients in functional class IV, as previously reported, but were not related to sFas. Conclusions. We found elevated levels of plasma sFas and no increase in plasma sFas-L in human CHF. The increase in sFas may play an important role in the pathophysiologic mechanisms of CHF. (J Am Coll Cardiol 1997;29:1214–20)" @default.
- W1972185183 created "2016-06-24" @default.
- W1972185183 creator A5000878423 @default.
- W1972185183 creator A5000978481 @default.
- W1972185183 creator A5013634345 @default.
- W1972185183 creator A5019887231 @default.
- W1972185183 creator A5022669876 @default.
- W1972185183 creator A5059374509 @default.
- W1972185183 creator A5059550230 @default.
- W1972185183 creator A5067787217 @default.
- W1972185183 creator A5077773904 @default.
- W1972185183 creator A5078951979 @default.
- W1972185183 creator A5082894446 @default.
- W1972185183 creator A5082969604 @default.
- W1972185183 creator A5083886640 @default.
- W1972185183 date "1997-05-01" @default.
- W1972185183 modified "2023-10-16" @default.
- W1972185183 title "Plasma Fas Ligand, an Inducer of Apoptosis, and Plasma Soluble Fas, an Inhibitor of Apoptosis, in Patients With Chronic Congestive Heart Failure" @default.
- W1972185183 cites W105127712 @default.
- W1972185183 cites W1517945724 @default.
- W1972185183 cites W1559184092 @default.
- W1972185183 cites W1671694443 @default.
- W1972185183 cites W1973792489 @default.
- W1972185183 cites W1975336660 @default.
- W1972185183 cites W1975369977 @default.
- W1972185183 cites W1984696190 @default.
- W1972185183 cites W2002507218 @default.
- W1972185183 cites W2005111715 @default.
- W1972185183 cites W2041466047 @default.
- W1972185183 cites W2048457755 @default.
- W1972185183 cites W2052853635 @default.
- W1972185183 cites W2056823828 @default.
- W1972185183 cites W2063254774 @default.
- W1972185183 cites W2068315718 @default.
- W1972185183 cites W2075809552 @default.
- W1972185183 cites W2088749722 @default.
- W1972185183 cites W2089843401 @default.
- W1972185183 cites W2093864493 @default.
- W1972185183 cites W2101462909 @default.
- W1972185183 cites W2120751716 @default.
- W1972185183 cites W2126636055 @default.
- W1972185183 cites W2127993518 @default.
- W1972185183 cites W2140852350 @default.
- W1972185183 cites W2143996326 @default.
- W1972185183 cites W2156475819 @default.
- W1972185183 cites W2157493207 @default.
- W1972185183 cites W2164802863 @default.
- W1972185183 cites W2232248512 @default.
- W1972185183 cites W2265871020 @default.
- W1972185183 cites W2324476825 @default.
- W1972185183 doi "https://doi.org/10.1016/s0735-1097(97)00055-7" @default.
- W1972185183 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9137215" @default.
- W1972185183 hasPublicationYear "1997" @default.
- W1972185183 type Work @default.
- W1972185183 sameAs 1972185183 @default.
- W1972185183 citedByCount "146" @default.
- W1972185183 countsByYear W19721851832012 @default.
- W1972185183 countsByYear W19721851832013 @default.
- W1972185183 countsByYear W19721851832014 @default.
- W1972185183 countsByYear W19721851832015 @default.
- W1972185183 countsByYear W19721851832016 @default.
- W1972185183 countsByYear W19721851832017 @default.
- W1972185183 countsByYear W19721851832018 @default.
- W1972185183 countsByYear W19721851832019 @default.
- W1972185183 countsByYear W19721851832020 @default.
- W1972185183 countsByYear W19721851832021 @default.
- W1972185183 countsByYear W19721851832022 @default.
- W1972185183 crossrefType "journal-article" @default.
- W1972185183 hasAuthorship W1972185183A5000878423 @default.
- W1972185183 hasAuthorship W1972185183A5000978481 @default.
- W1972185183 hasAuthorship W1972185183A5013634345 @default.
- W1972185183 hasAuthorship W1972185183A5019887231 @default.
- W1972185183 hasAuthorship W1972185183A5022669876 @default.
- W1972185183 hasAuthorship W1972185183A5059374509 @default.
- W1972185183 hasAuthorship W1972185183A5059550230 @default.
- W1972185183 hasAuthorship W1972185183A5067787217 @default.
- W1972185183 hasAuthorship W1972185183A5077773904 @default.
- W1972185183 hasAuthorship W1972185183A5078951979 @default.
- W1972185183 hasAuthorship W1972185183A5082894446 @default.
- W1972185183 hasAuthorship W1972185183A5082969604 @default.
- W1972185183 hasAuthorship W1972185183A5083886640 @default.
- W1972185183 hasBestOaLocation W19721851831 @default.
- W1972185183 hasConcept C126322002 @default.
- W1972185183 hasConcept C134018914 @default.
- W1972185183 hasConcept C170493617 @default.
- W1972185183 hasConcept C17991360 @default.
- W1972185183 hasConcept C190283241 @default.
- W1972185183 hasConcept C203014093 @default.
- W1972185183 hasConcept C2778198053 @default.
- W1972185183 hasConcept C3031857 @default.
- W1972185183 hasConcept C31573885 @default.
- W1972185183 hasConcept C502942594 @default.
- W1972185183 hasConcept C55493867 @default.
- W1972185183 hasConcept C66008609 @default.
- W1972185183 hasConcept C71924100 @default.
- W1972185183 hasConcept C86803240 @default.
- W1972185183 hasConceptScore W1972185183C126322002 @default.
- W1972185183 hasConceptScore W1972185183C134018914 @default.